The estimated Net Worth of Carl L Gordon is at least $37.2 Million dollars as of 13 August 2024. Mr. Gordon owns over 250,000 units of Prevail Therapeutics Inc stock worth over $2,684,464 and over the last 21 years he sold PRVL stock worth over $34,495,073. In addition, he makes $25,848 as Director at Prevail Therapeutics Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Gordon PRVL stock SEC Form 4 insiders trading
Carl has made over 19 trades of the Prevail Therapeutics Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he sold 250,000 units of PRVL stock worth $11,002,500 on 13 August 2024.
The largest trade he's ever made was buying 1,460,932 units of Prevail Therapeutics Inc stock on 4 May 2023 worth over $4,090,610. On average, Carl trades about 182,253 units every 139 days since 2004. As of 13 August 2024 he still owns at least 119,522 units of Prevail Therapeutics Inc stock.
You can see the complete history of Mr. Gordon stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Carl Gordon biography
Carl L. Gordon Ph.D. serves as Director of the Company. Dr. Gordon is a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors, LLC, an investment firm. Dr. Gordon currently serves on the board of directors of Keros Therapeutics Inc. (Nasdaq: KROS), Turning Point Therapeutics, Inc. (Nasdaq: TPTX), and a number of private companies. He previously served on the boards of Alector Inc. (Nasdaq: ALEC), ARMO BioSciences Inc., X4 Pharmaceuticals Inc. (formerly Arsanis Inc.) (Nasdaq: XFOR), Intellia Therapeutics, Inc. (Nasdaq: NTLA), Acceleron Pharma Inc., (Nasdaq: XLRN), Selecta BioSciences Inc. (Nasdaq: SELB), and Passage Bio Inc. (Nasdaq: PASG). Dr. Gordon received a B.A. in Chemistry from Harvard College, a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology and was a Fellow at The Rockefeller University. Gordon is qualified to serve on our board of directors due to his medical expertise, extensive business experience, and experience in venture capital and the life science industry.
What is the salary of Carl Gordon?
As the Director of Prevail Therapeutics Inc, the total compensation of Carl Gordon at Prevail Therapeutics Inc is $25,848. There are 8 executives at Prevail Therapeutics Inc getting paid more, with Asa Abeliovich having the highest compensation of $2,861,680.
How old is Carl Gordon?
Carl Gordon is 55, he's been the Director of Prevail Therapeutics Inc since 2017. There are 6 older and 5 younger executives at Prevail Therapeutics Inc. The oldest executive at Prevail Therapeutics Inc is Franz Hefti, 72, who is the Chief Development Officer.
What's Carl Gordon's mailing address?
Carl's mailing address filed with the SEC is C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421.
Insiders trading at Prevail Therapeutics Inc
Over the last 5 years, insiders at Prevail Therapeutics Inc have traded over $0 worth of Prevail Therapeutics Inc stock and bought 36,931,845 units worth $816,407,705 . The most active insiders traders include Acquisition Corp Eli Lilly ..., Peter A. Thompson, and Advisors Llc Orbi Med Capit.... On average, Prevail Therapeutics Inc executives and independent directors trade stock every 96 days with the average trade being worth of $138,767,762. The most recent stock trade was executed by Acquisition Corp Eli Lilly ... on 22 January 2021, trading 34,284,789 units of PRVL stock currently worth $771,407,753.
What does Prevail Therapeutics Inc's logo look like?
Complete history of Mr. Gordon stock trades at Acadia Pharmaceuticals Inc, Biocryst Pharmaceuticals, Intellia Therapeutics Inc, Pacira BioSciences Inc, Selecta Biosciences Inc, Turning Point Therapeutics Inc, Prevail Therapeutics Inc, Keros Therapeutics, Oric Pharmaceuticals, and Kinnate Biopharma
Prevail Therapeutics Inc executives and stock owners
Prevail Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Asa Abeliovich,
President, Chief Executive Officer, Director -
Jeffrey Sevigny,
Chief Medical Officer -
Yong Dai,
Chief Technology Officer -
Franz Hefti,
Chief Development Officer -
Francois Nader,
Independent Chairman of the Board -
Timothy Adams,
Independent Director -
Morgan Sheng,
Independent Director -
Ran Nussbaum,
Independent Director -
Carl Gordon,
Director -
Peter Thompson,
Independent Director -
William Carson,
Director -
Emily Minkow,
Chief Business Officer -
Kira Schwartz,
General Counsel -
Brett Kaplan,
Chief Financial Officer -
Advisors Llc Orbi Med Capit...,
-
Acquisition Corp Eli Lilly ...,